Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A phase I study of the Southern Italy Cooperative Oncology Group

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 915-921

  Comella, P ^a,c   Casaretti, R ^a   De Vita, F ^a   Avallone, A ^a   Orditura, M ^a   Petrillo, A ^a   Gravina, A ^a   Faranda, A ^b   Comis, S ^b   Comella, G ^a   Catalano, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Rhône Poulenc Rorer   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

5 fluorouracil; Advanced colorectal carcinoma; Biweekly regimen; Combination chemotherapy; CPT 11; First line treatment; Irinotecan

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DOSE CALCULATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0345425754     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008339010655     Document Type: Article

References (29)

1. Moertel CG. Chemotherapy of gastrointestinal cancer. N Engl J Med 1978; 299: 1049-52.
2. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in terms of response rate. J Clin Oncol 1992; 10: 896-903.
3. Giovannella BC, Stehlin JS, Wall ME et al. DNA Topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
4. Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51.
5. Canal P, Gay C, Dezeuse A et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996; 14: 2688-96.
6. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile. Semin Oncol 1996; 23 (Suppl. 3): 34-41.
7. Rothenberg ML. Topoisomerase I inhibitors: Review and update. Ann Oncol 1997; 8: 837-55.
8. Shimada Y, Yoshino M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
9. Rothember M, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-35.
10. Conti JA, Kemeny NE, Saltz LB et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-15.
11. 2 given every-other-week in previously treated colorectal cancer patients. Proc Thirty-Fourth Meet Am Soc Clin Oncol 1998; 1092: 284a.
12. Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 (Irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31A: 1283-7.
13. Rougier P, Van Cutsem E, Bajetta E et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1988; 352: 1407-12.
14. Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
15. Rothenberg ML, Pazdur R, Rowinsky EK et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC). Proc Thirty-Third Meet Am Soc Clin Oncol 1997; 944: 266a.
16. Van Cutsem E, Pozzo C, Starkjammar H et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998; 9: 1199-204.
17. Saltz LB, Kanowitz J, Kemeny NE et al. Phase I clinical trial and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996; 14: 2959-67.
18. Benhammouda A, Bastian G, Rixe O et al. A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination. Proc Thirty-Third Meet Am Soc Clin Oncol 1997; 710: 202a.
19. Rougier Ph, Ychou M, Seitz JF et al. Phase I-II study of CPT-11 in combination with LV + 5-FU ('De Gramont' regimen) every two weeks for the treatment of colorectal cancer (CRC) after 5-FU failure. Proc ECCO 9, Eur J Cancer 1997; 33 (Suppl 8): 756: S169.
20. Vanhoefer U, Harstrick A, Köhne CH et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17: 907-13.
21. Falcone A, Allegrini G, Masi G et al. Irinotecan in combination with leucovorin and 5-fluorouracil 48 hours continuous infusion: A phase I study with pharmacokinetic, DNA damage and topoisomerase I/DNA complexes evaluation in chemotherapy-naïve metastatic colorectal cancer patients. Proc Thirty-Fourth Meet Am Soc Clin Oncol 1998; 1117: 290a.
22. Garufi C, Tampellini M, D'Attino RM et al. A phase I study of CPT-11 plus chronomodulated (chrono) 5-fluorouracil (5-FU) and L-folinic acid (FA) in advanced colorectal cancer (ACC) patients. Proceedings of the 23rd Congress ESMO. Ann Oncol 1998; 9 (Suppl 4): 178O, 37.
23. Cornella P, Palmieri G, Lorusso V et al. Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur J Cancer 1996; 32A: 1719-26.
24. Miller AB, Hoogstraten B, Staquet M, Winkler V. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
25. Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodinamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51.
26. Abigerges D, Chabot GG, Armand J-P et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients. J Clin Oncol 1995; 13: 210-21.
27. Gay CC, Dezeuse A, Douillard JY et al. Pharmakokinetics and pharmakodinamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996; 14: 2688-95.
28. Vanhoefer U, Hapke G, Harstrick A et al. Schedule-dependent antitumor efficacy of irinotecan (CPT-11) and 5-fluorouracil (5-FU) in nude mice bearing colon tumor xenografts that are resistant to 5-FU. Proceedings of the 23rd ESMO Congress. Ann Oncol 1998; 9 (Suppl 4): 634P, 132.
29. 2) as first-line chemotherapy for metastatic colorectal cancer: Preliminary results of a multicentre phase II trial. Proceedings of the 23rd ESMO Congress. Ann Oncol 1998; 9 (Suppl 4): 181P, 38.